News & Updates

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

23 Dec 2024

The orally available and systemically acting small molecule modulator of sirtuin 6 (SIRT6) IMU-856 for coeliac disease demonstrates clinical activity with favourable safety profile, according to data from a phase 1 trial.

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

23 Dec 2024

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis

22 Dec 2024

QX004N, a humanized IgG1λ monoclonal antibody targeting IL-23, is superior to placebo in the treatment of patients with moderate to severe plaque psoriasis, according to a phase I trial.

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis

22 Dec 2024

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

Enlonstobart, a fully humanized and high-affinity anti-PD-1 immunoglobulin G4 monoclonal antibody, shows therapeutic potential in patients with PD-L1 positive recurrent or metastatic cervical cancer (r/mCC), while having an acceptable safety profile, according to an open-label phase II study.

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

22 Dec 2024

Obicetrapib cuts LDL-C in patients with HeFH

21 Dec 2024 by

Treatment with obicetrapib, a CETP* inhibitor, significantly reduced low-density lipoprotein cholesterol (LDL-C) levels for up to 1 year in patients with heterozygous familial hypercholesterolaemia (HeFH), despite being on maximally tolerated lipid-lowering therapy, according to the BROOKLYN trial presented at AHA 2024.

Obicetrapib cuts LDL-C in patients with HeFH

21 Dec 2024

Seniors with T2D fare well with oral semaglutide in real world

20 Dec 2024 by

Oral semaglutide, when used in routine clinical practice, appears effective in managing type 2 diabetes (T2D) even in “very elderly” populations.

Seniors with T2D fare well with oral semaglutide in real world

20 Dec 2024

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

20 Dec 2024 by

In the AIRFLO study, treatment with ziresovir – a potent, selective, orally administered RSV F protein inhibitor – leads to a greater resolution of signs and symptoms of bronchiolitis in hospitalized infants and young children with respiratory syncytial virus (RSV) infection.

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

20 Dec 2024

Original New Drug Application Approvals by US FDA (1-15 December 2024)

20 Dec 2024

New drug applications approved by US FDA as of 1-15 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 December 2024)

20 Dec 2024

Nemolizumab works well for prurigo nodularis

19 Dec 2024

Targeting interleukin-31 signalling with nemolizumab appears to produce substantial improvements in core signs and symptoms of prurigo nodularis (PN), as shown in the phase III OLYMPIA 1 trial.

Nemolizumab works well for prurigo nodularis

19 Dec 2024

Rotavirus jabs in NICU more beneficial than risky

18 Dec 2024 by

New research shows limited transmission of the rotavirus vaccine strains in neonatal intensive care units (NICUs), suggesting that the benefits of vaccination outweigh earlier concerns.

Rotavirus jabs in NICU more beneficial than risky

18 Dec 2024

Pembrolizumab extends survival in advanced melanoma

18 Dec 2024 by

Patients with advanced melanoma achieve long-term survival with the use of pembrolizumab, as shown by the results of the 10-year follow-up of the phase III KEYNOTE-006 study.

Pembrolizumab extends survival in advanced melanoma

18 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

Novel small-molecule modulator for coeliac disease promising in phase 1 trial

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis

Anti–IL-23 monoclonal antibody shows promise in plaque psoriasis

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

Novel PD-1 inhibitor shows activity against PD-L1 positive recurrent or metastatic cervical cancer

Obicetrapib cuts LDL-C in patients with HeFH

Obicetrapib cuts LDL-C in patients with HeFH

Seniors with T2D fare well with oral semaglutide in real world

Seniors with T2D fare well with oral semaglutide in real world

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

AIRFLO supports therapeutic potential of ziresovir for RSV in infants, young children

Original New Drug Application Approvals by US FDA (1-15 December 2024)

Original New Drug Application Approvals by US FDA (1-15 December 2024)

Nemolizumab works well for prurigo nodularis

Nemolizumab works well for prurigo nodularis

Rotavirus jabs in NICU more beneficial than risky

Rotavirus jabs in NICU more beneficial than risky

Pembrolizumab extends survival in advanced melanoma

Pembrolizumab extends survival in advanced melanoma